GLP-1 and GIP Agonists: A Triple Ripple in Obesity Medication Series
Semaglutide: A First-Generation GLP-1 Agonist Semaglutide is an anti-diabetic medication used for the treatment of type 2 diabetes and obesity. It works as a GLP-1 agonist, increasing insulin secretion and improving blood sugar control. By slowing down digestion,...
GLP-1 and GIP Agonists: A Triple Ripple in Obesity Medication Series
Tirzepatide: A Second-Generation Medication Tirzepatide is another medication used to improve blood sugar control in adults. It has a greater affinity for GIP receptors than GLP-1 receptors, making it more effective in reducing hyperglycemia. Studies have shown that...
GLP-1 and GIP Agonists: A Triple Ripple in Obesity Medication Series
The Promise of Retatrutide In the pipeline, there’s an experimental drug called Retatrutide, which is showing promising results in Phase II clinical trials. Also known as LY-3437943, Retatrutide is a triple hormone receptor against GLP-1, GIP, and GCR-GR...
GLP-1 and GIP Agonists: A Triple Ripple in Obesity Medication Series
Addressing Concerns About Muscle Loss Some individuals have expressed concerns about muscle loss while taking these medications. However, maintaining muscle mass is crucial for metabolism and longevity. By combining Semaglutide and Tirzepatide weight loss therapy with...
GLP-1 and GIP Agonists: A Triple Ripple in Obesity Medication Series
Optimizing Health with Vitamin Supplements While on these medications, it’s important to monitor vitamin D and B12 levels. Studies have shown that supplementation with oral vitamins is not effective in raising deficient levels. Injection-based supplementation is...
